Netherlands Pharma market growth held back by govt generics policy
The Netherlands’ pharmaceutical market value will rise slowly from around $6.7 billion in 2014 to $7.2 billion by 2020, with growth restricted by the government’s focus on generic drugs as a cost-containment too, new research indicates.
According to research and consulting firm GlobalData’s latest report, the introduction of preference policies by health insurers has played a significant role in the increasing share of prescriptions dispensed as generic medicines.
Generic substitution at the pharmacy level and drugs prescribed by their International Non-proprietary Name (INN) are permitted in the Netherlands, and physicians have adopted an electronic prescribing system through which the brand name of a drug automatically converts to the INN name.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze